StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Aggregate of 7 sell-side ratings as of 2025-03-01. Stonvex does not endorse these ratings.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $1.01 | $1.02 | +0.99% | 0.0M |
| 05-15 | $1.00 | $1.03 | +2.99% | 0.1M |
| 05-18 | $1.04 | $0.93 | -10.24% | 1.0M |
| 05-19 | $0.95 | $0.93 | -2.28% | 0.0M |
| 05-20 | $0.91 | $0.92 | +0.99% | 0.1M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Each factor shows RDHL's percentile within the scored universe — observational ranking, not a recommendation.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.
Fundamentals not available for RDHL yet.
We pull from FMP, Finnhub, and Polygon — common gaps are very recent IPOs that haven't filed their first 10-Q, pink-sheet OTC tickers, and foreign filers without US-listed depth. The Financials tab reads SEC EDGAR directly and may still have data here.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.